Alcohol intake and porphyria cutanea tarda

Clinics in Dermatology

Volumn 17, Issue 4, 1999, Pages 431-436

  Elder, George H ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; IRON; UROPORPHYRINOGEN DECARBOXYLASE;

ALCOHOL CONSUMPTION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; ENZYME INACTIVATION; HEME SYNTHESIS; HUMAN; PATHOGENESIS; PORPHYRIA CUTANEA TARDA; PORPHYRIN METABOLISM; PRIORITY JOURNAL; RISK FACTOR;

ALCOHOLISM; ANIMALS; ETHANOL; HUMANS; PORPHYRIA CUTANEA TARDA; RISK FACTORS; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 0032828295     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00029-2     Document Type: Conference Paper

References (55)

1. Brunsting L.A. Observations in porphyria cutanea tarda. Arch Dermatol Syphil. 70:1954;551-564.
2. Grossman M.E., Bickers D.R., Poh-Fitzpatrick M.B., et al. Porphyria cutanea tarda Clinical features and laboratory findings in 40 patients . Am J Med. 67:1979;277-286.
3. Lopez-Miras A., De Salamanca R.E., Garcia-Perez A., et al. Porphyria cutanea tarda as seen in Madrid. Boll dell'Instituto Dematol S Gallicano. 8:1987;335-336.
4. Herrero C., Vicente A., Bruguera M., et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet. 341:1993;788-789.
5. Stolzel U., Kostler E., Koszka C., et al. Low prevalence of hepatitis C virus infection in Germany. Hepatology. 21:1995;1500-1503.
6. Fargion S., Fracanzani A.L., Romano R., et al. Genetic hemochromatosis in Italian patients with porphyria cutanea tarda Possible explanation for iron overload . J Hepatol. 24:1996;564-569.
7. Bonkovsky H.L., Poh-Fitzpatrick M., Pimstone N., et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 27:1998;1661-1669.
8. Elder G.H. Porphyria cutanea tarda. Semin Liver Dis. 18:1998;67-75.
9. De Matteis F. Porphyria cutanea tarda of the toxic and sporadic varieties. Clin Dematol. 16:1998;265-266.
10. Kappas A., Sassa S., Galbraith R.A., Nordmann Y. The porphyrias. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The molecular and metabolic basis of inherited disease. 7th ed. 1995;2103-2159 McGraw-Hill, New York.
11. Garey J.R., Franklin K.F., Brown A.D., et al. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterology. 105:1993;165-169.
12. Elder G.H. Genetic defects in the porphyrias Types and significance . Clin Dermatol. 16:1998;225-234.
13. Rocchi E., Gibertini P., Cassanelli M., et al. Iron removal therapy in porphyria cutanea tarda Phlebotomy versus slow subcutaneous desferrioxamine infusion . Br J Dermatol. 114:1986;621-629.
14. Ashton R.E., Hawk J.L.M., Magnus I.A. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol. 111:1981;609-613.
15. Bruguera M. Liver involvement in porphyria. Semin Dermatol. 5:1986;178-185.
16. Bengtsson N.O., Handell L. Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer. 54:1986;115-117.
17. Heikel T., Lockwood W., Rimington C. Formation of non-enzymic haem. Nature. 182:1958;313-315.
18. Halten J., Krook H. Follow-up studies on an unselected ten-year material of 360 patients with liver cirrhosis in one community. Acta Med Scand. 173:1963;479-487.
19. Dehlin O., Enerback L., Lundvall O. Porphyria cutanea tarda A genetic disease? Acta Med Scand. 194:1973;265-270.
20. Elder G.H. Porphyrin metabolism in porphyria cutanea tarda. Semin Hematol. 14:1977;227-242.
21. Edwards C.Q., Griffen L.M., Goldgar D.E., et al. HLA-linked hemochromatosis alleles in sporadic porphyria cutanea tarda. Gastroenterology. 97:1989;972-981.
22. Bonkovsky H.L., Banner B.F., Lambrecht R.W., et al. Iron in liver disease other than hemochromatosis. Semin Liver Dis. 16:1996;65-82.
23. Felsher B.J., Kushner J.P. Hepatic siderosis and porphyria cutanea tarda Relation of iron excess to the metabolic defect . Semin Hematol. 14:1977;243-252.
24. Elder G.H., Urquhart A.J., De Salamanca R.E., et al. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet. 2:1985;229-233.
25. Moran M.J., Fontanellas A., Brudieux E., et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients The influence of virus C infection . Hepatology. 27:1998;584-589.
26. Kondon M., Shimizu Y. The effects of ethanol, estrogen, and hexachlorobenzene on the activities of hepatic δ-aminolevulinate synthetase, δ-aminolevulinate dehydratase, and uroporphyrinogen decarboxylase in male rats. Arch Toxicol. 59:1986;141-145.
27. Teschke R., Gorys-Konemann C., Daldrup T., et al. Influence of chronic alcohol consumption on hepatic heme and porphyrin metabolism. Biochem Pharmacol. 36:1987;1133-1138.
28. Doss M., Von Tiepermann R., Stutz G., et al. Alcohol-induced decrease in uroporphyrinogen decarboxylase activity in rat liver and spleen. Enzyme. 26:1981;24-31.
29. Irving M.G., Halliday J.W., Powell L.W. Association between alcoholism and increased hepatic iron stores. Alcohol Clin Exp Res. 12:1988;7-13.
30. McColl K.E.L., Thompson G.G., Moore M.R., et al. Abnormal haem biosynthesis in chronic alcoholics. Eur J Clin Invest. 11:1981;461-468.
31. Watson C.J., Sutherland D., Hawkinson V. Studies of coproporphyrin The isomer distribution and per diem excretion of urinary coproporphyrin in cases of cirrhosis of the liver . J Lab Clin Med. 37:1954;8-28.
32. Aziz M.A., Schwartz S., Watson C.J. Studies of coproporphyrin III Re-investigation of isomer distribution in jaundice and liver disease . J Lab Clin Med. 63:1964;596-604.
33. Elder G.H., Roberts A.G. Uroporphyrinogen decarboxylase. J Biomembr Bioenerg. 27:1995;207-214.
34. Sinclair P., Gorman N., Sinclair J., et al. Ascorbic acid inhibits chemically-induced uroporphyria in ascorbate-requiring rats. Hepatology. 22:1995;565-572.
35. Sinclair P., Gorman N., Steven I., et al. Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med. 130:1997;197-201.
36. McColl K.E.L., Thompson G.G., Moore M.R., et al. Acute ethanol ingestion and haem biosynthesis in healthy subjects. Eur J Clin Invest. 10:1980;107-112.
37. Schoenfeld N., Mamet R., Leibovici L., et al. Alcohol-induced changes in urinary aminolevulinic acid and porphyrins Unrelated to liver disease . Alcohol. 13:1996;59-63.
38. Koszo F., Siklosi C.S., Simon N. Effects of iron-loading and ethanol treatment on rat porphyrin metabolism. Pharmacol Biochem Behav. 13:1980;325-329.
39. Wrighton S.A., Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 22:1992;1-21.
40. Sinclair J., Jeffery E., Wrighton S., et al. Alcohol-mediated increases in acetaminophen hepatotoxicity. Biochem Pharmacol. 55:1998;1557-1565.
41. Shanley B.C., Zail S.S., Joubert S.M. Effect of ethanol on liver δ-aminolevulinate synthetase in rats. Lancet. 1:1968;70-77.
42. Shanley B.C., Zail S.S., Joubert S.M. Effect of ethanol on liver δ-aminolevulinate synthetase and urinary porphyrin excretion in symptomatic porphyria. Br J Hematol. 17:1969;389-396.
43. Bonkovsky H.L., Pomeroy J.S. Human hepatic δ-aminolevulinate synthetase Requirement of an endogenous system for succinyl-coenzyme A generation to demonstrate increased activity in cirrhotic and anticonvulsant-treated subjects . Clin Sci Mol Med. 52:1977;509-521.
44. Tsukamoto H., Horne W., Kamimura S., et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:1995;620-630.
45. Day C.P., James O.F.W. Steatohepatitis A tale of two "hits"? Gastroenterology. 1998;842-845.
46. Schiff E. Hepatitis C and alcohol. Hepatology. 26:1997;395-425.
47. Bonkovsky H.L., Banner B.F., Rothman A.L. Iron and chronic viral hepatitis. Hepatology. 25:1997;759-768.
48. Farinati F., Cardin R., DeMaria N., et al. Iron storage, lipid peroxidation and glutathione turnover in chronic HCV-positive hepatitis. J Hepatol. 22:1995;449-456.
49. Sinclair P., Gorman N., Walton H.S., et al. Ascorbic acid inhibition of cytochrome P450-catalysed uroporphyrin accumulation. Arch Biochem Biophys. 304:1993;464-470.
50. Sinclair P.R., Gorman N., Dalton T., et al. Uroporphyria produced in mice by iron and 5-aminolevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem J. 330:1998;149-153.
51. Francis J.E., Smith A.G. Oxidation of uroporphyrinogen by hydroxyl radicals Evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase . FEBS Lett. 233:1988;311-314.
52. Lucas D., Berthou F., Dréano Y., et al. Comparison of leveles of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples. Alcohol Clin Exp Res. 17:1993;900-905.
53. Sinclair PR, Gorman N, Tsylov IB, et al. Uroporphyrinogen oxidation catalysed by human cytochromes P450. Drug Metab Dispos (in press).
54. Akhtar R, Smith AG. Chromosomal linkage analysis of porphyria in mice induced by hexachlorobenzene-iron synergism: A model of sporadic porphyria cutanea tarda. Pharmacogenetics (in press).
55. Elder G.H., Worwood M. Mutations in the hemochromatosis (HFE) gene, porphyria cutanea tarda and iron overload. Hepatology. 27:1998;289-291.